Study Examines Dolutegravir-Based HIV Treatment Outcomes in Cameroon

A recent retrospective study conducted at the Bamenda Regional Hospital HIV Treatment Centre in Cameroon has evaluated the real-world effectiveness of a tenofovir, lamivudine, and dolutegravir (TLD) combination regimen. Following a 2019 World Health Organization recommendation favoring dolutegravir-based therapies, researchers reviewed medical records to assess viral suppression levels among adults receiving routine care. The evaluation focused on participants with high medication adherence and no recorded comorbidities.

High Rates of Virologic Suppression Observed

Out of 368 records screened, 157 patients met the strict eligibility criteria, comprising both treatment-naïve individuals and those who had switched from previous therapies. By the six-month mark, 95.5 percent of the participants achieved virologic suppression, defined as under 1,000 copies per milliliter. This proportion increased to 99.4 percent at 12 months, with only a single participant experiencing confirmed virologic failure who was subsequently transitioned to a second-line regimen. The median weight change across the cohort over the course of a year was an increase of 2.0 kilograms.

What to know: While the findings point toward favorable outcomes for a dolutegravir-based regimen, researchers emphasize important limitations. Because the analysis was observational, relied on a small, highly adherent, and comorbidity-free sample from a single hospital, and lacked a control group, the results cannot establish direct causality or be generalized to the broader patient population. Readers should consult a qualified healthcare provider for personalized medical advice regarding HIV treatment options.